EGFR and neoplasm: To identify the changes in mitogenic signalling pathways that inhibit tumour growth in the mouse model, we transiently knocked down DHHC20 in an oncogenic Kras-harbouring lung adenocarcinoma cell line NCI-H23 and examined the differences in signalling downstream of EGFR [40].